Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
- Conditions
- Interventions
- Procedure: Surgical resectionOther: Educational and Media InterventionOther: SOC, Educational and Media InterventionProcedure: Ommaya/VPSDrug: MethotrexateDrug: CisplatinDrug: VincristineDrug: CyclophosphamideDrug: CarboplatinDrug: TopotecanDrug: PegfilgrastimDrug: EtoposideDrug: FilgrastimRadiation: Irradiation
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05535166
- Locations
- 🇺🇸
Primary Children's Hospital, Salt Lake City, Utah, United States
🇺🇸Lucille Packard Children's Hospital at Stanford University, Palo Alto, California, United States
🇺🇸Orlando Health Arnold Palmer Hospital for Children, Orlando, Florida, United States
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 260
- Registration Number
- NCT05436418
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸City of Hope, Duarte, California, United States
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Ayman H Qasrawi
- Registration Number
- NCT05330377
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Venetoclax to Augment Epigenetic Modification and Chemotherapy
- First Posted Date
- 2022-04-07
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 40
- Registration Number
- NCT05317403
- Locations
- 🇺🇸
Children's Wisconsin, Milwaukee, Wisconsin, United States
Treateament of Newly Diagnosed Acute Monocytic Leukemia in Children
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2023-07-27
- Target Recruit Count
- 43
- Registration Number
- NCT05313958
- Locations
- 🇨🇳
Guangzhou First People's Hospital, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Maternal and Child Health Hospital of Foshan, Foshan, Guangdong, China
PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 68
- Registration Number
- NCT05222035
- Locations
- 🇨🇳
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Ossium Health, Inc.
- Registration Number
- NCT05170828
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
- Conditions
- Interventions
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05115630
- Locations
- 🇺🇸
M D Anderson Caner Center, Houston, Texas, United States
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Leland Metheny
- Target Recruit Count
- 16
- Registration Number
- NCT05052957
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT05032183
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.